China Clarifies Position on Forged Trial Data As 30 Applications Are Rejected
Executive Summary
As more new drug applications get rejected under the China Food and Drug Administration’s drive to stamp out trial data forgery, the regulator has issued draft guidance to clarify its position on data integrity breaches.
You may also be interested in...
China Probe Reveals Widespread Drug Data Violations At Major Study Centers
Severe adverse events left unreported, critical data gone missing, subject drugs substituted to pass bioequivalent testing - these are just some of the wrongdoings disclosed by the China Food and Drug Administration in a rare report on regulatory transgressions during drug trials conducted in the country.
Chinese regulator surprises pharma with clinical data self-audit notice
A China Food and Drug Administration announcement released on July 22 is requiring the drug applicants in over 1,600 pending product approvals to conduct self-audits of the clinical data and submit an electronic version of the reports to the CFDA’s Center for Drug and Food Inspection1.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.